Estimated reading time: 5 minutes
Thank you for reading this post, Please bookmark onetrader.in website for regular updates!
🏥 Gujarat Kidney & Super Speciality Ltd. IPO 2025 — Full Details, Analysis & Investment View
Gujarat Kidney & Super Speciality Ltd. is launching its initial public offering (IPO) in December 2025 — a fresh equity issue aimed at raising ₹250.8 crore for expansion, acquisitions and capacity enhancement across its healthcare network. This IPO brings one of Gujarat’s prominent regional multispeciality hospital chains to the Indian stock market, targeting both retail and institutional investors.
📊 IPO Key Details
| Parameter | Detail |
|---|---|
| IPO Open Date | 22 December 2025 |
| IPO Close Date | 24 December 2025 |
| Price Band | ₹108 – ₹114 per share |
| Face Value | ₹2 per share |
| Lot Size | 128 shares (min) — approx ₹14,592 at upper band |
| Issue Size | ~₹250.8 crore (fresh issue) |
| Issue Type | Fresh issue (100% to company) |
| Equity Shares Offered | 2.20 crore shares |
| Allotment Date | 26 Dec 2025 (expected) |
| Refund / Demat Credit | 29 Dec 2025 (expected) |
| Tentative Listing Date | 30 Dec 2025 on NSE & BSE |
| Exchanges | NSE & BSE |
🏥 Company Overview
Gujarat Kidney & Super Speciality Ltd. is a regional healthcare services provider headquartered in Gujarat, India. It operates a network of multispeciality hospitals and pharmacies focused on secondary and tertiary care. The company’s footprint includes:
- Seven multispeciality hospitals across key cities in Gujarat
- Four in-house pharmacies
- A total bed capacity of ~490 beds (with ~340 operational beds)
- Services covering general surgery, critical care, nephrology, orthopaedics, cardiology, laparoscopic procedures and more
The company has grown via a combination of organic expansions and strategic acquisitions, positioning itself as a comprehensive healthcare provider in the western and central Gujarat regions. Flattrade
💰 Business Model & Operations
Gujarat Kidney & Super Speciality earns revenue primarily through:
1. Hospital Services
Fees from inpatient and outpatient treatments, surgeries, diagnostics and specialised care.
2. Pharmacy Operations
Revenue from retail pharmacy sales located within and outside hospital premises.
3. Tertiary/Speciality Services
Procedures such as dialysis, joint replacements, minimally invasive surgeries, orthopaedics and cardiology treatments.
This diversified revenue model helps the company balance cyclical variations in patient inflows and optimise asset utilisation.
🚀 Why This IPO Matters
Unlike typical offer-for-sale IPOs, Gujarat Kidney & Super Speciality’s IPO is a fresh issue — meaning 100% of the proceeds will flow into the company for growth initiatives. This is a positive signal for investors looking for expansion-oriented stories in the healthcare sector.
The healthcare sector in India continues to grow due to rising healthcare awareness, increasing insurance penetration, and demand for quality medical infrastructure beyond metros.
📌 Use of IPO Proceeds
Funds raised through the IPO will be deployed for:
- Acquisition of Parekhs Hospital in Ahmedabad
- Expansion of facilities and capacity at existing hospitals
- Capital expenditure for a new hospital setup in Vadodara
- Purchase of advanced medical equipment including robotics
- Repayment or prepayment of certain secured borrowings
- Funding inorganic growth through future acquisitions
- General corporate purposes
These uses reflect a strategic focus on capacity enhancement, technology upgrades and geographic expansion.
📈 Investment Highlights
✔ Fresh Issue — Capital for Growth
Funds raised will be used to expand services and facilities, rather than rewarding existing shareholders.
✔ Operating Presence in Key Gujarat Markets
The company’s hospitals serve Tier-2 and Tier-3 cities, capitalising on rising demand for quality regional healthcare.
✔ Diversified Healthcare Portfolio
A mix of secondary and tertiary services with strong multidisciplinary capabilities.
✔ Anchor Investor Support
The IPO raised ₹100 crore from anchor investors before public bidding, indicating institutional interest.
✔ Grey Market Sentiment
Early grey market premium (GMP) activity suggests positive listing expectations, with GMP trending upward in recent days.
⚠️ Risks & Considerations
❗ Limited Track Record
As a regional player, the company has a limited national presence compared to larger listed hospital chains.
❗ Capital-Intensive Business
Healthcare services require continuous investment in infrastructure, technology and specialised talent.
❗ Regulatory & Operational Risks
Policies related to healthcare pricing, quality standards and labour laws could impact operations.
❗ Profitability & Utilisation Metrics
Hospital performance can vary based on bed occupancy rates, payor mix and operational efficiency.
❗ Localised Demand Risk
A heavy revenue concentration within Gujarat could make the business sensitive to regional economic changes or healthcare policy shifts.
🧠 Onetrader Investment View
Gujarat Kidney & Super Speciality’s IPO represents a growth-oriented healthcare play with a clear expansion roadmap. Investors looking to add exposure to India’s booming healthcare sector — especially in regional hospital infrastructure and speciality care — could find this IPO interesting.
📊 What Makes It Attractive
- Fresh funds focused on growth
- Demand for quality regional healthcare
- Clear expansion & acquisition plans
⚠ Points to Watch
- Execution risk in new hospital projects
- Profitability trends as capacity ramps up
- Macro healthcare demand patterns
Onetrader Rating: ⭐⭐⭐☆☆ (3.5/5) — Good long-term potential with execution risk; best suited for investors with a horizon beyond 12–18 months.
📚 FAQs
Q1. When is the Gujarat Kidney IPO?
IPO opens on 22 Dec 2025 and closes on 24 Dec 2025.
Q2. What is the price band?
The price band is ₹108 to ₹114 per share.
Q3. What is the lot size?
Each lot consists of 128 shares.
Q4. What is the issue size?
The IPO size is ~₹250.80 crore via fresh equity issuance.
Q5. When will shares be listed?
Tentative listing date is 30 Dec 2025 on NSE & BSE.